Abstract
Reactive oxygen species and reactive nitrogen species are produced endogenously by cardiomyocytes and are fundamental signaling molecules that regulate cellular function. Production of ROS and RNS is finely tuned to maintain proper myocardial function, but is altered in many pathophysiological conditions, therefore contributing to worsening myocardial dysfunction and ultimately heart failure. Indeed, an excess of ROS and RNS is central in many pathways leading to cardiac hypertrophy and failure, and the correct regulation of the nitroso-redox balance is fundamental for the function of the main components of the EC-coupling machinery. Broad antioxidant therapies have been proposed to improve myocardial function, but these therapies blunt even physiological ROS and RNS signaling, bringing limited, if any, beneficial effect. On the other hand, more targeted interventions on specific sources or pathways may produce promising results.
Keywords: Cardiac hypertrophy, excitation contraction coupling, heart failure, myocardial function, reactive nitrogen species, reactive oxygen species.
Current Drug Targets
Title:Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Volume: 16 Issue: 8
Author(s): Carlo G. Tocchetti, Marilisa Molinaro, Tommaso Angelone, Vincenzo Lionetti, Rosalinda Madonna, Fabio Mangiacapra, Francesco Moccia, Claudia Penna, Laura Sartiani, Federico Quaini and Pasquale Pagliaro
Affiliation:
Keywords: Cardiac hypertrophy, excitation contraction coupling, heart failure, myocardial function, reactive nitrogen species, reactive oxygen species.
Abstract: Reactive oxygen species and reactive nitrogen species are produced endogenously by cardiomyocytes and are fundamental signaling molecules that regulate cellular function. Production of ROS and RNS is finely tuned to maintain proper myocardial function, but is altered in many pathophysiological conditions, therefore contributing to worsening myocardial dysfunction and ultimately heart failure. Indeed, an excess of ROS and RNS is central in many pathways leading to cardiac hypertrophy and failure, and the correct regulation of the nitroso-redox balance is fundamental for the function of the main components of the EC-coupling machinery. Broad antioxidant therapies have been proposed to improve myocardial function, but these therapies blunt even physiological ROS and RNS signaling, bringing limited, if any, beneficial effect. On the other hand, more targeted interventions on specific sources or pathways may produce promising results.
Export Options
About this article
Cite this article as:
G. Tocchetti Carlo, Molinaro Marilisa, Angelone Tommaso, Lionetti Vincenzo, Madonna Rosalinda, Mangiacapra Fabio, Moccia Francesco, Penna Claudia, Sartiani Laura, Quaini Federico and Pagliaro Pasquale, Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC), Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150304103517
DOI https://dx.doi.org/10.2174/1389450116666150304103517 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
Current Vascular Pharmacology An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Strategies for Skeletal Muscle Targeting in Drug Discovery
Current Pharmaceutical Design Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy Evaluation of Blood Oxidant/Antioxidant Changes and Testicular Toxicity after Subacute Exposure to Cadmium in Albino Rats: Therapeutic Effect of <i>Nigella sativa</i> Seed Extracts
Combinatorial Chemistry & High Throughput Screening High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Protease Inhibitors in the Clinic
Medicinal Chemistry Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]
Current Pharmaceutical Design Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Cranberry as Promising Natural Source of Potential Anticancer Agents: Current Evidence and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Canonical Wnt/Beta-Catenin Signaling Network as Emerging Signaling Cascade for Therapeutic Intervention in Chronic Renal Disease
Current Drug Targets Predictive Value of Biomarkers in Patients with Heart Failure
Current Medicinal Chemistry Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report
Current Drug Safety Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design